Glutathione...not a believer yet????

dramamama · May 23, 2008

Abstract - selected Article
Figures/Tables
References
Purchase PDF (110 K)
E-mail Article
Add to my Quick Links

Related Articles in ScienceDirect
Acute renal failure in CF patients chronically infected...
Journal of Cystic Fibrosis
252 First capsule endoscopy studies in Cystic Fibrosis:...
Journal of Cystic Fibrosis
253 Laparascopic fundoplication is an effective and saf...
Journal of Cystic Fibrosis
View More Related Articles

doi:10.1016/j.jcf.2008.03.006
Copyright © 2008 European Cystic Fibrosis Society Published by Elsevier B.V.
Case Study

Improvement in clinical markers in CF patients using a reduced glutathione regimen: An uncontrolled, observational study

Alfredo Visca, Clark T. Bishop, Sterling C. Hilton and Valerie M. Hudson

Pediatric Pulmonologist, ASL Cuneo 1, Piedmont, Italy - CF Section

Pulmonologist, Provo, Utah, United States

Brigham Young University, United States

Received 19 June 2007; revised 30 January 2008; accepted 14 March 2008. Available online 21 May 2008.

Abstract

CFTR mutation, which causes cystic fibrosis (CF), has also recently been identified as causing glutathione system dysfunction and systemic deficiency of reduced glutathione (GSH). Such dysfunction and deficiency regarding GSH may contribute to the pathophysiology of CF. We followed 13 patients (age range 1 - 27 years) with cystic fibrosis who were using a regimen of reduced glutathione (GSH), including oral glutathione and inhaled buffered glutathione in an uncontrolled, observational study. Dosage ranged from 66 - 148 mg/kg/day in divided doses, and the term examined was the initial 5.5 months of GSH use (45 days of incrementally adjusted dose, plus 4 months of use at full dosage). Baseline and post-measurements of FEV1 percent predicted, BMI percentile, and weight percentile were noted, in addition to bacterial status and pulmonary exacerbations. Significant improvement in the following clinical parameters was observed: average improvement in FEV1 percent predicted (N = 10) was 5.8 percentage points (p < 0.0001), average weight percentile (N = 13) increased 8.6 points (p < 0.001), BMI percentile (N = 11) improved on average 1.22 points (p < 0.001). All patients improved in FEV1 and BMI, if measured in their case; 12 of 13 patients improved in weight percentile. Positive sputum cultures of bacteria in 11 patients declined from 13 to 5 (p < 0.03) with sputum cultures of Pseudomonas aeruginosa becoming negative in 4 of 5 patients previously culturing PA, including two of three patients chronically infected with PA as determined by antibody status. Use of a daily GSH regimen appears to be associated in CF patients with significant improvement in lung function and weight, and a significant decline in bacteria cultured in this uncontrolled study. These findings bear further clinical investigation in larger, randomized, controlled studies.

Keywords: Inflammation; FEV1; BMI; Weight percentile; Pseudomonas aeruginosa

Article Outline

dramamama · May 23, 2008

Abstract - selected Article
Figures/Tables
References
Purchase PDF (110 K)
E-mail Article
Add to my Quick Links

Related Articles in ScienceDirect
Acute renal failure in CF patients chronically infected...
Journal of Cystic Fibrosis
252 First capsule endoscopy studies in Cystic Fibrosis:...
Journal of Cystic Fibrosis
253 Laparascopic fundoplication is an effective and saf...
Journal of Cystic Fibrosis
View More Related Articles

doi:10.1016/j.jcf.2008.03.006
Copyright © 2008 European Cystic Fibrosis Society Published by Elsevier B.V.
Case Study

Improvement in clinical markers in CF patients using a reduced glutathione regimen: An uncontrolled, observational study

Alfredo Visca, Clark T. Bishop, Sterling C. Hilton and Valerie M. Hudson

Pediatric Pulmonologist, ASL Cuneo 1, Piedmont, Italy - CF Section

Pulmonologist, Provo, Utah, United States

Brigham Young University, United States

Received 19 June 2007; revised 30 January 2008; accepted 14 March 2008. Available online 21 May 2008.

Abstract

CFTR mutation, which causes cystic fibrosis (CF), has also recently been identified as causing glutathione system dysfunction and systemic deficiency of reduced glutathione (GSH). Such dysfunction and deficiency regarding GSH may contribute to the pathophysiology of CF. We followed 13 patients (age range 1 - 27 years) with cystic fibrosis who were using a regimen of reduced glutathione (GSH), including oral glutathione and inhaled buffered glutathione in an uncontrolled, observational study. Dosage ranged from 66 - 148 mg/kg/day in divided doses, and the term examined was the initial 5.5 months of GSH use (45 days of incrementally adjusted dose, plus 4 months of use at full dosage). Baseline and post-measurements of FEV1 percent predicted, BMI percentile, and weight percentile were noted, in addition to bacterial status and pulmonary exacerbations. Significant improvement in the following clinical parameters was observed: average improvement in FEV1 percent predicted (N = 10) was 5.8 percentage points (p < 0.0001), average weight percentile (N = 13) increased 8.6 points (p < 0.001), BMI percentile (N = 11) improved on average 1.22 points (p < 0.001). All patients improved in FEV1 and BMI, if measured in their case; 12 of 13 patients improved in weight percentile. Positive sputum cultures of bacteria in 11 patients declined from 13 to 5 (p < 0.03) with sputum cultures of Pseudomonas aeruginosa becoming negative in 4 of 5 patients previously culturing PA, including two of three patients chronically infected with PA as determined by antibody status. Use of a daily GSH regimen appears to be associated in CF patients with significant improvement in lung function and weight, and a significant decline in bacteria cultured in this uncontrolled study. These findings bear further clinical investigation in larger, randomized, controlled studies.

Keywords: Inflammation; FEV1; BMI; Weight percentile; Pseudomonas aeruginosa

Article Outline

dramamama · May 23, 2008

Abstract - selected Article
Figures/Tables
References
Purchase PDF (110 K)
E-mail Article
Add to my Quick Links

Related Articles in ScienceDirect
Acute renal failure in CF patients chronically infected...
Journal of Cystic Fibrosis
252 First capsule endoscopy studies in Cystic Fibrosis:...
Journal of Cystic Fibrosis
253 Laparascopic fundoplication is an effective and saf...
Journal of Cystic Fibrosis
View More Related Articles

doi:10.1016/j.jcf.2008.03.006
Copyright © 2008 European Cystic Fibrosis Society Published by Elsevier B.V.
Case Study

Improvement in clinical markers in CF patients using a reduced glutathione regimen: An uncontrolled, observational study

Alfredo Visca, Clark T. Bishop, Sterling C. Hilton and Valerie M. Hudson

Pediatric Pulmonologist, ASL Cuneo 1, Piedmont, Italy - CF Section

Pulmonologist, Provo, Utah, United States

Brigham Young University, United States

Received 19 June 2007; revised 30 January 2008; accepted 14 March 2008. Available online 21 May 2008.

Abstract

CFTR mutation, which causes cystic fibrosis (CF), has also recently been identified as causing glutathione system dysfunction and systemic deficiency of reduced glutathione (GSH). Such dysfunction and deficiency regarding GSH may contribute to the pathophysiology of CF. We followed 13 patients (age range 1 - 27 years) with cystic fibrosis who were using a regimen of reduced glutathione (GSH), including oral glutathione and inhaled buffered glutathione in an uncontrolled, observational study. Dosage ranged from 66 - 148 mg/kg/day in divided doses, and the term examined was the initial 5.5 months of GSH use (45 days of incrementally adjusted dose, plus 4 months of use at full dosage). Baseline and post-measurements of FEV1 percent predicted, BMI percentile, and weight percentile were noted, in addition to bacterial status and pulmonary exacerbations. Significant improvement in the following clinical parameters was observed: average improvement in FEV1 percent predicted (N = 10) was 5.8 percentage points (p < 0.0001), average weight percentile (N = 13) increased 8.6 points (p < 0.001), BMI percentile (N = 11) improved on average 1.22 points (p < 0.001). All patients improved in FEV1 and BMI, if measured in their case; 12 of 13 patients improved in weight percentile. Positive sputum cultures of bacteria in 11 patients declined from 13 to 5 (p < 0.03) with sputum cultures of Pseudomonas aeruginosa becoming negative in 4 of 5 patients previously culturing PA, including two of three patients chronically infected with PA as determined by antibody status. Use of a daily GSH regimen appears to be associated in CF patients with significant improvement in lung function and weight, and a significant decline in bacteria cultured in this uncontrolled study. These findings bear further clinical investigation in larger, randomized, controlled studies.

Keywords: Inflammation; FEV1; BMI; Weight percentile; Pseudomonas aeruginosa

Article Outline

dramamama · May 23, 2008

Abstract - selected Article
Figures/Tables
References
Purchase PDF (110 K)
E-mail Article
Add to my Quick Links

Related Articles in ScienceDirect
Acute renal failure in CF patients chronically infected...
Journal of Cystic Fibrosis
252 First capsule endoscopy studies in Cystic Fibrosis:...
Journal of Cystic Fibrosis
253 Laparascopic fundoplication is an effective and saf...
Journal of Cystic Fibrosis
View More Related Articles

doi:10.1016/j.jcf.2008.03.006
Copyright © 2008 European Cystic Fibrosis Society Published by Elsevier B.V.
Case Study

Improvement in clinical markers in CF patients using a reduced glutathione regimen: An uncontrolled, observational study

Alfredo Visca, Clark T. Bishop, Sterling C. Hilton and Valerie M. Hudson

Pediatric Pulmonologist, ASL Cuneo 1, Piedmont, Italy - CF Section

Pulmonologist, Provo, Utah, United States

Brigham Young University, United States

Received 19 June 2007; revised 30 January 2008; accepted 14 March 2008. Available online 21 May 2008.

Abstract

CFTR mutation, which causes cystic fibrosis (CF), has also recently been identified as causing glutathione system dysfunction and systemic deficiency of reduced glutathione (GSH). Such dysfunction and deficiency regarding GSH may contribute to the pathophysiology of CF. We followed 13 patients (age range 1 - 27 years) with cystic fibrosis who were using a regimen of reduced glutathione (GSH), including oral glutathione and inhaled buffered glutathione in an uncontrolled, observational study. Dosage ranged from 66 - 148 mg/kg/day in divided doses, and the term examined was the initial 5.5 months of GSH use (45 days of incrementally adjusted dose, plus 4 months of use at full dosage). Baseline and post-measurements of FEV1 percent predicted, BMI percentile, and weight percentile were noted, in addition to bacterial status and pulmonary exacerbations. Significant improvement in the following clinical parameters was observed: average improvement in FEV1 percent predicted (N = 10) was 5.8 percentage points (p < 0.0001), average weight percentile (N = 13) increased 8.6 points (p < 0.001), BMI percentile (N = 11) improved on average 1.22 points (p < 0.001). All patients improved in FEV1 and BMI, if measured in their case; 12 of 13 patients improved in weight percentile. Positive sputum cultures of bacteria in 11 patients declined from 13 to 5 (p < 0.03) with sputum cultures of Pseudomonas aeruginosa becoming negative in 4 of 5 patients previously culturing PA, including two of three patients chronically infected with PA as determined by antibody status. Use of a daily GSH regimen appears to be associated in CF patients with significant improvement in lung function and weight, and a significant decline in bacteria cultured in this uncontrolled study. These findings bear further clinical investigation in larger, randomized, controlled studies.

Keywords: Inflammation; FEV1; BMI; Weight percentile; Pseudomonas aeruginosa

Article Outline

dramamama · May 23, 2008

Abstract - selected Article
 Figures/Tables
 References
 Purchase PDF (110 K)
 E-mail Article
 Add to my Quick Links
 
 
 
 
 
 Related Articles in ScienceDirect
 Acute renal failure in CF patients chronically infected...
 Journal of Cystic Fibrosis
 252 First capsule endoscopy studies in Cystic Fibrosis:...
 Journal of Cystic Fibrosis
 253 Laparascopic fundoplication is an effective and saf...
 Journal of Cystic Fibrosis
 View More Related Articles
 
 doi:10.1016/j.jcf.2008.03.006
 Copyright © 2008 European Cystic Fibrosis Society Published by Elsevier B.V.
 Case Study
 
 Improvement in clinical markers in CF patients using a reduced glutathione regimen: An uncontrolled, observational study
 
 Alfredo Visca, Clark T. Bishop, Sterling C. Hilton and Valerie M. Hudson
 
 Pediatric Pulmonologist, ASL Cuneo 1, Piedmont, Italy - CF Section
 
 Pulmonologist, Provo, Utah, United States
 
 Brigham Young University, United States
 
 
 Received 19 June 2007; revised 30 January 2008; accepted 14 March 2008. Available online 21 May 2008.
 
 Abstract
 
 CFTR mutation, which causes cystic fibrosis (CF), has also recently been identified as causing glutathione system dysfunction and systemic deficiency of reduced glutathione (GSH). Such dysfunction and deficiency regarding GSH may contribute to the pathophysiology of CF. We followed 13 patients (age range 1 - 27 years) with cystic fibrosis who were using a regimen of reduced glutathione (GSH), including oral glutathione and inhaled buffered glutathione in an uncontrolled, observational study. Dosage ranged from 66 - 148 mg/kg/day in divided doses, and the term examined was the initial 5.5 months of GSH use (45 days of incrementally adjusted dose, plus 4 months of use at full dosage). Baseline and post-measurements of FEV1 percent predicted, BMI percentile, and weight percentile were noted, in addition to bacterial status and pulmonary exacerbations. Significant improvement in the following clinical parameters was observed: average improvement in FEV1 percent predicted (N = 10) was 5.8 percentage points (p < 0.0001), average weight percentile (N = 13) increased 8.6 points (p < 0.001), BMI percentile (N = 11) improved on average 1.22 points (p < 0.001). All patients improved in FEV1 and BMI, if measured in their case; 12 of 13 patients improved in weight percentile. Positive sputum cultures of bacteria in 11 patients declined from 13 to 5 (p < 0.03) with sputum cultures of Pseudomonas aeruginosa becoming negative in 4 of 5 patients previously culturing PA, including two of three patients chronically infected with PA as determined by antibody status. Use of a daily GSH regimen appears to be associated in CF patients with significant improvement in lung function and weight, and a significant decline in bacteria cultured in this uncontrolled study. These findings bear further clinical investigation in larger, randomized, controlled studies.
 
 Keywords: Inflammation; FEV1; BMI; Weight percentile; Pseudomonas aeruginosa
 
 Article Outline

Faust · May 23, 2008

Well the problem is, it wasn't controlled. But the high point was "with sputum cultures of Pseudomonas aeruginosa becoming negative in 4 of 5 patients previously culturing PA". I never stuck with the glutathione thing, mostly due to cost and me investigating other supplements. But our insurance companies need to seriously help us out with supplements when we take something for a period of time and show improvement.

I remember glutathione to be expensive for me due to my body size/mass. Just for inhalation of the good stuff, for my body weight, it was very expensive, when a bottle that will last a week or two at my doseage basically costs 30ish dollars. I'm drained enough for what i'm on, I can't hang with another 100 bucks of supplements a month just to try and keep healthy.

But any news is good news.

On a side note to this story...I went off pharmanac due to cost concerns, and I was feeling great. I went maybe a month or so. I did notice my sputum thicker. For a long time I had much more non mucoid vs mucoid sputum. After being off the pharmanac I notice more dark mucoid spots, and my mucous doesn't flow as freely as it did before. So I bit the bullet and throwed down an additional 80 bucks for a month and 1/2 of pharma nac. For those of us on hardcore supplementation, just try to imagine what we spend on our supplements AND all of our regular care/prescriptions.

Faust · May 23, 2008

Well the problem is, it wasn't controlled. But the high point was "with sputum cultures of Pseudomonas aeruginosa becoming negative in 4 of 5 patients previously culturing PA". I never stuck with the glutathione thing, mostly due to cost and me investigating other supplements. But our insurance companies need to seriously help us out with supplements when we take something for a period of time and show improvement.

I remember glutathione to be expensive for me due to my body size/mass. Just for inhalation of the good stuff, for my body weight, it was very expensive, when a bottle that will last a week or two at my doseage basically costs 30ish dollars. I'm drained enough for what i'm on, I can't hang with another 100 bucks of supplements a month just to try and keep healthy.

But any news is good news.

On a side note to this story...I went off pharmanac due to cost concerns, and I was feeling great. I went maybe a month or so. I did notice my sputum thicker. For a long time I had much more non mucoid vs mucoid sputum. After being off the pharmanac I notice more dark mucoid spots, and my mucous doesn't flow as freely as it did before. So I bit the bullet and throwed down an additional 80 bucks for a month and 1/2 of pharma nac. For those of us on hardcore supplementation, just try to imagine what we spend on our supplements AND all of our regular care/prescriptions.

Faust · May 23, 2008

Well the problem is, it wasn't controlled. But the high point was "with sputum cultures of Pseudomonas aeruginosa becoming negative in 4 of 5 patients previously culturing PA". I never stuck with the glutathione thing, mostly due to cost and me investigating other supplements. But our insurance companies need to seriously help us out with supplements when we take something for a period of time and show improvement.

I remember glutathione to be expensive for me due to my body size/mass. Just for inhalation of the good stuff, for my body weight, it was very expensive, when a bottle that will last a week or two at my doseage basically costs 30ish dollars. I'm drained enough for what i'm on, I can't hang with another 100 bucks of supplements a month just to try and keep healthy.

But any news is good news.

On a side note to this story...I went off pharmanac due to cost concerns, and I was feeling great. I went maybe a month or so. I did notice my sputum thicker. For a long time I had much more non mucoid vs mucoid sputum. After being off the pharmanac I notice more dark mucoid spots, and my mucous doesn't flow as freely as it did before. So I bit the bullet and throwed down an additional 80 bucks for a month and 1/2 of pharma nac. For those of us on hardcore supplementation, just try to imagine what we spend on our supplements AND all of our regular care/prescriptions.

Faust · May 23, 2008

Well the problem is, it wasn't controlled. But the high point was "with sputum cultures of Pseudomonas aeruginosa becoming negative in 4 of 5 patients previously culturing PA". I never stuck with the glutathione thing, mostly due to cost and me investigating other supplements. But our insurance companies need to seriously help us out with supplements when we take something for a period of time and show improvement.

I remember glutathione to be expensive for me due to my body size/mass. Just for inhalation of the good stuff, for my body weight, it was very expensive, when a bottle that will last a week or two at my doseage basically costs 30ish dollars. I'm drained enough for what i'm on, I can't hang with another 100 bucks of supplements a month just to try and keep healthy.

But any news is good news.

On a side note to this story...I went off pharmanac due to cost concerns, and I was feeling great. I went maybe a month or so. I did notice my sputum thicker. For a long time I had much more non mucoid vs mucoid sputum. After being off the pharmanac I notice more dark mucoid spots, and my mucous doesn't flow as freely as it did before. So I bit the bullet and throwed down an additional 80 bucks for a month and 1/2 of pharma nac. For those of us on hardcore supplementation, just try to imagine what we spend on our supplements AND all of our regular care/prescriptions.

Faust · May 23, 2008

Well the problem is, it wasn't controlled. But the high point was "with sputum cultures of Pseudomonas aeruginosa becoming negative in 4 of 5 patients previously culturing PA". I never stuck with the glutathione thing, mostly due to cost and me investigating other supplements. But our insurance companies need to seriously help us out with supplements when we take something for a period of time and show improvement.
 
 
 I remember glutathione to be expensive for me due to my body size/mass. Just for inhalation of the good stuff, for my body weight, it was very expensive, when a bottle that will last a week or two at my doseage basically costs 30ish dollars. I'm drained enough for what i'm on, I can't hang with another 100 bucks of supplements a month just to try and keep healthy.
 
 But any news is good news.
 
 
 On a side note to this story...I went off pharmanac due to cost concerns, and I was feeling great. I went maybe a month or so. I did notice my sputum thicker. For a long time I had much more non mucoid vs mucoid sputum. After being off the pharmanac I notice more dark mucoid spots, and my mucous doesn't flow as freely as it did before. So I bit the bullet and throwed down an additional 80 bucks for a month and 1/2 of pharma nac. For those of us on hardcore supplementation, just try to imagine what we spend on our supplements AND all of our regular care/prescriptions.

AnD · May 23, 2008